343 related articles for article (PubMed ID: 25502234)
1. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability.
Garg P; Dhakne R; Belekar V
Mol Divers; 2015 Feb; 19(1):163-72. PubMed ID: 25502234
[TBL] [Abstract][Full Text] [Related]
2. The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood-brain barrier (BBB) permeability.
Lingineni K; Belekar V; Tangadpalliwar SR; Garg P
Mol Divers; 2017 May; 21(2):355-365. PubMed ID: 28050687
[TBL] [Abstract][Full Text] [Related]
3. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
5. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Miller DW; Hinton M; Chen F
Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
[TBL] [Abstract][Full Text] [Related]
7. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
8. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
10. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
11. Altered glycaemia differentially modulates efflux transporter expression and activity in hCMEC/D3 cell line.
Sajja RK; Cucullo L
Neurosci Lett; 2015 Jun; 598():59-65. PubMed ID: 25982326
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
[TBL] [Abstract][Full Text] [Related]
13. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2).
Nicolazzo JA; Katneni K
Curr Top Med Chem; 2009; 9(2):130-47. PubMed ID: 19200001
[TBL] [Abstract][Full Text] [Related]
14. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.
Poller B; Drewe J; Krähenbühl S; Huwyler J; Gutmann H
Cell Mol Neurobiol; 2010 Jan; 30(1):63-70. PubMed ID: 19629677
[TBL] [Abstract][Full Text] [Related]
15. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
[TBL] [Abstract][Full Text] [Related]
18. BCRP at the blood-brain barrier: genomic regulation by 17β-estradiol.
Mahringer A; Fricker G
Mol Pharm; 2010 Oct; 7(5):1835-47. PubMed ID: 20735085
[TBL] [Abstract][Full Text] [Related]
19. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
20. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.
Hoque MT; Shah A; More V; Miller DS; Bendayan R
J Neurochem; 2015 Dec; 135(6):1113-22. PubMed ID: 26465636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
